Bortezomib drug used in –
The question is asking which condition Bortezomib is used for. The correct answer is multiple myeloma. But wait, I should make sure. The options weren't provided, but since the correct answer is given, I can work from there. Let me think about the other options that might be there. Common distractors could be other cancers like lymphoma, leukemia, or even non-cancerous conditions like rheumatoid arthritis. But Bortezomib is specifically for multiple myeloma.
Now, the core concept section needs to mention that Bortezomib is a proteasome inhibitor used in multiple myeloma. The correct answer explanation should detail how it works by inhibiting proteasomes, leading to apoptosis in myeloma cells. Also, maybe mention its role in treating mantle cell lymphoma as a secondary use.
For the wrong options, if I assume the options are other diseases, I need to explain why they're incorrect. For example, if an option is breast cancer, Bortezomib isn't a standard treatment there. Similarly, if an option is a bacterial infection, it's not applicable. I should make sure each wrong option is addressed with a clear reason.
The clinical pearl should highlight that Bortezomib is a key drug in multiple myeloma treatment and note its side effects like peripheral neuropathy. That's a common exam point. Also, maybe mention that it's administered via IV or subcutaneously.
I need to check the formatting rules. The explanation should be in markdown, with bold sections but no headers. Keep each section concise. Make sure the answer ends with the correct answer line. Avoid using any markdown except bold and line breaks. Let me structure each section step by step, ensuring clarity and that all parts are covered within the character limit.
**Core Concept:** Bortezomib is a proteasome inhibitor used primarily in the treatment of multiple myeloma and mantle cell lymphoma. It functions by blocking the proteasome, which disrupts protein degradation in cancer cells, leading to apoptosis.
**Why the Correct Answer is Right:** Bortezomib is a cornerstone therapy for multiple myeloma. By inhibiting the 26S proteasome, it prevents the degradation of misfolded or damaged proteins, inducing endoplasmic reticulum stress and activating apoptosis pathways in plasma cells. It is also approved for mantle cell lymphoma and relapsed/refractory myeloma, often in combination with corticosteroids or immunomodulators.
**Why Each Wrong Option is Incorrect:**
**Option A:** If the option were "Breast Cancer," Bortezomib is not a first-line treatment for breast malignancies.
**Option B:** If the option were "Rheumatoid Arthritis," Bortezomib lacks efficacy in autoimmune arthritis.
**Option C:** If the option were "Bacterial Infections," Bortezomib has no role in treating infections; it targets neoplastic cells.
**Clinical Pearl /